A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
This study is testing a new cancer medicine called LOXO-783, both by itself and with other cancer treatments. Researchers want to see how safe it is and how well it works for advanced breast cancer and other solid tumors that have a specific genetic change called a PIK3CA mutation.
You might be able to join if you have advanced breast cancer or another solid tumor with the required PIK3CA gene change. Participants must also have finished previous cancer treatments, have healthy organ function, and be able to go about their daily activities.
You will receive the study medication, and possibly other approved or experimental cancer treatments, while doctors closely monitor your health and safety. Participation can last up to three years or even longer if the treatment is helping you.
This study is currently recruiting participants and has locations in cities like Scottsdale, Arizona, as well as Los Angeles and San Francisco, California.
- 1Tests a new medication called LOXO-783 for specific tumors
- 2Requires a specific genetic change known as a PIK3CA mutation
- 3Study locations are currently open and recruiting in Arizona and California
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.